Matthew Riley | Head, IR & Corporate Communications |
Alfred Altomari | Chairman & CEO |
Dennis Reilly | SVP & CFO |
Oren Livnat | H.C. Wainwright & Co. |
Leland Gershell | Oppenheimer |
Timothy Lugo | William Blair & Company |
Nazibur Rahman | Maxim Group |
Good afternoon, and welcome to the Agile Therapeutics' First Quarter 2021 Financial Results Conference Call. Please note today's event is being recorded. I would now like to turn the conference over to Matt Riley, Head of Investors Relations.
Hello, everyone, and welcome to today's conference call to discuss our first quarter 2021 financial results and corporate update.
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, management's expectations for our future financial and operational performance, our business strategy, our assessment of the combined hormonal contraceptive market, and the potential market share for Twirla among other statements regarding our plans, prospects and expectations.